ADAP
Adaptimmune Therapeutics
ADAP
ADAP
Delisted
ADAP was delisted on the 27th of October, 2025.
84 hedge funds and large institutions have $624M invested in Adaptimmune Therapeutics in 2021 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
11% less call options, than puts
Call options by funds: $982K | Put options by funds: $1.11M
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
Holders
84
Holding in Top 10
–
Calls
$982K
Puts
$1.11M
Top Buyers
| 1 | +$5.89M | |
| 2 | +$4.69M | |
| 3 | +$3.49M | |
| 4 |
OAMG
Odey Asset Management Group
London,
United Kingdom
|
+$2.92M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.89M |
Top Sellers
| 1 | -$13.5M | |
| 2 | -$4.2M | |
| 3 | -$3.53M | |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.52M |
| 5 |
PA
Perceptive Advisors
New York
|
-$2.16M |